Louis Garguilo
ARTICLES BY LOUIS
-
![Boat ON Beach]( "How To Find Your Safe-Harbor Consultant")
12/8/2020Dublin-based Orphan Drug Consulting founder Evelyn Kelly explains how to navigate to the consultants right for you. Hint: It doesn’t include longer term contracts, but may a good dose of advice – free of charge.
-
![Lab Worker]( "Meet Your New “Person”-In-Plant: iPad On IV, Ph.D.")
12/1/2020Joseph Graskemper of Translate Bio was recently involved in a process to create a V-PIP [virtual person-in-plant] at his CDMO. Turns out to be something that should carry on post-COVID-19, and prompt readers and your service providers to some ingenuity of your own.
-
![Kid Superhero]( "Primal Motivations: Stop Drug Shortages, Start Domestic Supply Chains")
11/21/2020“So in the spring of 2019,” recalls Eric Edwards, “I put my doctor’s white coat back on, and shadow Dr. Marshall Summar at Children’s National Hospital for a week ...” Part 3 of my exclusive interview w/ the CEO of Phlow Corporation – the motives, mission, and message.
-
![Businessman with suitcase looking at startup icons]( "What's A “Biopharma CDMO”?")
11/15/2020In part two of my exclusive interview with Phlow Corporation's CEO Dr. Eric Edwards, we turn our attention to biopharma business models and CDMO partnerships.
-
![Question Box]( "You Don't Know Phlow: The Backstory Of A Misread Biopharma Start-Up")
11/9/2020No biopharma start-up has been as misconstrued, hastily judged in strategy and capability, or even labeled “political.” Now Phlow Corporation’s CEO Eric Edwards sets the record straight in an exclusive interview.
-
![Truck]( "Where Have All The “Early Amgens” Gone? To Tech Transfers, Every One")
11/1/2020“My opinion is not theoretical. It reflects having seen it in action at Amgen, from 1986 to 1995, with the launching of Epogen & Neupogen.” Like biopharma’s Nietzsche, Mark Witcher wants us to slay outdated beliefs – “tech transfer” being a prime target.
-
![Arrow Circle]( "The Witcher Way: Can We “Eliminate” Tech Transfer?")
10/18/2020“You can call me a revolutionary, if you like,” responds Mark Witcher upon my comment he is. His thesis on the elimination of "tech transfer" is detailed, and provocative. But is it practical? Readers will make the ultimate judgment.
-
![Cheering Crowd]( "Tech Transfer, Self-Esteem, And A Fitting Facility")
10/14/2020“This is akin to making the process for the tech transfer as efficient as you are trying to make the process to produce the actual material.” Part 2 of our “dissertation” on the mental and physical state of tech transfer in drug development and manufacturing outsourcing.
-
![Books]( "A Real Dissertation On Tech Transfer")
10/10/2020A biopharma professional is earning a degree in tech transfer. Literally. Here’s some of what he’s learned, including the four thorns in the side of those transferring drug development and manufacturing projects to CDMOs.
-
![375_250-istock_1132089008]( "Outsourcing Trend Of The Year? The CDMO Synergy Sprint")
10/4/2020Two more CDMOs – this time in Germany – announce their best-in-breed alliance. What are these partnerships all about? Will this trend benefit readers looking for the best outsourcing outcomes?
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.